pioneer 9 semaglutide Dose-response, efficacy, and safety of oral monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial Efficacy, safety and cardiovascular outcomes

It is important to distinguish between direct pharmacological effects and indirect consequences of treatment

glucagon receptor activation stimulates -oxidation of fatty acids, reducing hepatic lipid content, while GLP-1 enhances systemic insulin sensitivity and decreases lipolysis in adipose tissue, thereby indirectly reducing hepatic fat influx (51)

We recommend that you adopt supportive lifestyle changes like a balanced diet and regular physical activity to maintain a healthy weight after treatment ends

Cold medication typically causes more injection site discomfort

The safety protocols for peptide handling exist for a reason